ACE NanoMed Limited

Project Leader(s):
Prof. Anna TSANG
Key Technology Area:
Industrial Sector(s):
Pharmaceutical and Healthcare Products
Click here to contact us


ACE NanoMed is a Research and Development company aiming to commercialize innovative therapeutics with highly specific targeting effect to Epstein-Barr virus (EBV)-associated malignancies, including nasopharyngeal carcinoma (NPC), gastric cancer, Burkitt's lymphoma and Hodgkin lymphoma. We strive to implement mRNA-based and aptamer-based nanomedicine into clinical practice for patient treatments. These drugs are devised to target and induce the death of EBV-infected cancer cells, thereby sparing the normal cells in the body safe from the therapy, as well as lessening the side effects endured by the patients.


We utilize the special association of EBV infection to these malignancies to invent mRNA-based and DNA-based nanoparticles for therapeutic purposes.

Therapeutic #1:
“Anti-tumor immune commander” – mRNA therapeutic vaccine which encodes EBV antigens for training anti-cancer T cell responses to EBV-infected cancer cells.

Therapeutic #2:
“Target killer” – Aptamers which can deliver the traditional chemodrugs specifically to EBV-infected cancer cells.

“Smart bomb” - mRNA lipid-nanoparticles which can elicit cytolytic virus activation (CLVA) therapy for specific killing of EBV-positive cancer cells.

The three drugs of ACE NanoMed can be applied individually or used in combination as three attack fronts in the battlefield of fighting EBV-infected cancer cells.